Wyeth

Jonathan Laird Gross

Gary Paul Stack

Dahui Zhou

Hong Gao

Albert Jean Robichaud

Marla Jean Williams

Ji-In Kim

William Ronald Solvibile

Richard Eric Mewshaw

Derek Cecil Cole

Reinhardt Bernhard Baudy

Megan Tran

Gavin David Heffernan

Magda Asselin

Alexander Greenfield

Joseph Raymond Stock

Nicole T Hatzenbuhler

George E M Husbands

Jean Yi-ching Sze

John Dunlop

Alessandro Mazzacani

The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor: wherein the variables are described in the specification.

N-substituted-azacyclylamines as histamine-3 antagonists

The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor. 

The present invention provides a compound of formula Ia: 

Aminoalkylazole derivatives as histamine-3 antagonists

Compounds of formula 1 or pharmaceutically acceptable salts thereof are provided: which are agonists and partial agonists of the 2c subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.

Dihydrobenzofuranyl alkanamines and methods for using same as cns agents

Compounds of formula I are provided: wherein each of R, R, y, m, n, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of melatoninergic receptors. The compounds, and compositions containing the compounds, can be used to treat melatoninergic disorders.

Dihydrobenzofuran derivatives and uses thereof

Compounds of Formula 1 or pharmaceutically acceptable salts thereof are provided: which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.

Dihydrobenzofuranyl alkanamine derivatives and methods for using same

Compounds of formula I or pharmaceutically acceptable salts thereof are provided: wherein each of R, R, R, R, R, n, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.

Benzofuranyl alkanamine derivatives and uses thereof

Compounds of formula I or pharmaceutically acceptable salts thereof are provided: wherein each of R, R, R, R, y, m, n, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.

Chromane and chromene derivatives and uses thereof

Quinoline 3-amino chroman derivatives and compositions containing such compounds are disclosed. Methods for using the quinoline 3-amino chroman derivatives and compositions containing such compounds in the treatment of serotonin disorders are disclosed. Also disclosed are processes for preparing quinoline 3-amino chroman derivatives.

Quinoline 3-amino chroman derivatives

Compounds of the formula:are useful for the treatment of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse and related illnesses.

Growing community of inventors

Cranbury, NJ, United States of America

Jonathan Laird Gross